Department of Psychiatry, New York University Langone School of Medicine, 550 First Ave, New York, NY 10016, United States.
Pharmacol Biochem Behav. 2011 Dec;100(2):330-9. doi: 10.1016/j.pbb.2011.08.021. Epub 2011 Aug 26.
Several lines of research have now suggested the controversial hypothesis that the central noradrenergic system acts to exacerbate depression as opposed to having an antidepressant function. If correct, lesions of this system should increase resistance to depression, which has been partially but weakly supported by previous studies. The present study reexamined this question using two more recent methods to lesion noradrenergic neurons in mice: intraventricular (ivt) administration of either the noradrenergic neurotoxin, DSP4, or of a dopamine-β-hydroxylase-saporin immunotoxin (DBH-SAP ITX) prepared for mice. Both agents given 2 weeks prior were found to significantly increase resistance to depressive behavior in several tests including acute and repeated forced swims, tail suspension and endotoxin-induced anhedonia. Both agents also increased locomotor activity in the open field. Cell counts of brainstem monoaminergic neurons, however, showed that both methods produced only partial lesions of the locus coeruleus and also affected the dorsal raphe or ventral tegmental area. Both the cell damage and the antidepressant and hyperactive effects of ivt DSP4 were prevented by a prior i.p. injection of the NE uptake blocker, reboxetine. The results are seen to be consistent with recent pharmacological experiments showing that noradrenergic and serotonergic systems function to inhibit active behavior. Comparison with previous studies utilizing more complete and selective LC lesions suggest that mouse strain, lesion size or involvement of multiple neuronal systems are critical variables in the behavioral and affective effects of monoaminergic lesions and that antidepressant effects and hyperactivity may be more likely to occur if lesions are partial and/or involve multiple monoaminergic systems.
现在有几条研究线索提出了一个有争议的假说,即中枢去甲肾上腺素能系统的作用是加剧抑郁,而不是具有抗抑郁作用。如果正确的话,这个系统的病变应该会增加对抑郁的抵抗力,以前的研究在一定程度上但很微弱地支持了这一假说。本研究使用两种更新的方法来研究这个问题,即用脑室(ivt)内给予去甲肾上腺素能神经毒素 DSP4 或为小鼠制备的多巴胺-β-羟化酶-蓖麻毒素免疫毒素(DBH-SAP ITX)来损伤去甲肾上腺素能神经元。发现这两种药物在 2 周前给予时,在包括急性和重复强迫游泳、悬尾和内毒素引起的快感缺失在内的几种测试中,均能显著增加对抑郁行为的抵抗力。这两种药物也增加了开阔场中的运动活动。然而,脑干部位单胺能神经元的细胞计数显示,这两种方法仅产生了蓝斑的部分病变,并且还影响了中缝背核或腹侧被盖区。脑室 DSP4 的细胞损伤以及抗抑郁和激活作用均可通过预先腹腔内注射 NE 摄取阻滞剂 reboxetine 来预防。结果与最近的药理学实验一致,表明去甲肾上腺素能和 5-羟色胺能系统的作用是抑制主动行为。与以前利用更完全和选择性 LC 病变的研究相比,提示小鼠品系、病变大小或多个神经元系统的参与是单胺能病变对行为和情感影响的关键变量,如果病变是部分的和/或涉及多个单胺能系统,则抗抑郁作用和激活作用更有可能发生。